GCL
CLDI icon

Glazer Capital LLC’s Calidi Biotherapeutics CLDI Stock Holding History

Glazer Capital LLC’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-195
Closed -$3.85M – 214
2023
Q1 		$3.85M Buy
+195
New +$3.83M 0.21% 111

Other funds holding CLDI

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
EC
Elequin Capital New York $3.36B AUM 11.23% 1-Year Est. Return
QL
Quarry LP New York $1.2B AUM 47.63% 1-Year Est. Return

Glazer Capital LLC's CLDI Position: Q2 2023 in Review

Glazer Capital LLC sold out of Calidi Biotherapeutics (CLDI) in Q2 2023, closing a stake of 195 shares — an estimated $3.85M sold.

Glazer Capital LLC first reported a position in CLDI in Q1 2023 and held it in 1 quarter. The position peaked at $3.85M in Q1 2023. 24 funds tracked by Wall St. Rank hold CLDI as of Q2 2023.

  • Glazer Capital LLC reported no remaining Calidi Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Glazer Capital LLC sold 195 Calidi Biotherapeutics shares in Q2 2023, an estimated $3.85M.
  • Glazer Capital LLC first reported a position in Calidi Biotherapeutics in Q1 2023 and held it in 1 quarter.
  • Glazer Capital LLC's Calidi Biotherapeutics position peaked at $3.85M in Q1 2023.
  • 24 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2023.

Based on Glazer Capital LLC's 13F filing for Q2 2023, filed 14 Aug 2023.